BOCA RATON, FL -- (Marketwire) -- 08/25/09 -- David H. Fater, CEO of Vicor Technologies,
Inc. (OTCBB: VCRT), today announced that original research conducted using
its PD2i algorithm to prospectively predict risk of sudden cardiac death
was published in Therapeutics and Clinical Risk Management (2009-5, 1-12).
Vicor Technologies is a biotechnology company focused on the
commercialization of innovative, non-invasive medical devices and
diagnostics using its patented, proprietary PD2i algorithm and software to
stratify patients at risk of sudden cardiac death (SCD) and trauma victims
in need of life saving intervention.
"Comparison of linear-stochastic and nonlinear-deterministic algorithms in
the analysis of 15-minute clinical ECGs to predict risk of arrhythmic
death" documents the comparative evaluation of nonlinear algorithms and
conventional linear-stochastic measures of heartbeat series in low-to-high
risk cardiac patients to prospectively predict risk of arrhythmic (sudden
cardiac) death. Vicor's time-dependent, non-linear PD2i algorithm was
demonstrated to be the comparatively superior test.
"We are gratified to have this study accepted for publication in
Therapeutics and Clinical Risk Management," stated Mr. Fater. "Acceptance
in this prestigious, peer-reviewed journal attests to the quality and rigor
of the research in which the PD2i is involved. We are also heartened by
the results, which attest once again to the PD2i's ability to prospectively
predict those at risk of arrhythmic or sudden cardiac death with a high
degree of accuracy and consistency," he concluded.
"Comparison of linear-stochastic and nonlinear-deterministic algorithms in
the analysis of 15-minute clinical ECGs to predict risk of arrhythmic
death" chronicles the study of 397 patients admitted to three emergency
room departments for chest pain and determined to be at low-to-high risk of
acute myocardial infarction (MI). Fifteen-minute ECGs were recorded and
R-R intervals assessed by three non-linear algorithms (PD2i, DFA, ApEn) and
four conventional linear-stochastic measures (SDNN, MNN, 1/f-Slope, LF/HF).
The sensitivity and relative risk for predicting arrhythmic death was
highest at all time-points for the PD2i algorithm.
Therapeutics and Clinical Risk Management, a Dove Press publication, is an
international, peer-reviewed journal of clinical therapeutics and risk
management focusing on concise rapid reporting of clinical studies in all
therapeutic areas, outcomes, safety, and programs for the effective, safe,
and sustained use of medicines.
